Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Animal Models

Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis

International Journal of Obesity volume 41, pages 1702–1709 (2017)Cite this article

Subjects

Abstract

Background:

Obesity is known as an epidemic worldwide because of consumption of westernized high-fat diets and one of the major risk factors of hypertension. Histone deacetylases (HDACs) control gene expression by regulating histone/non-histone protein deacetylation. HDAC inhibitors exert anti-cancer and anti-inflammatory effects and play a protective role in cardiovascular diseases. In the present study, we tested the effect of an FDA-approved pan-HDAC inhibitor valproic acid (VPA) on high-fat diet (HFD)-induced hypertension in mice. Furthermore, we examined the mechanism of VPA-induced prevention of hypertension.

Methods:

Nine-week-old male C57BL/6 mice were fed either a normal diet (ND) or HFD. When the HFD group reached a pre-hypertensive phase (130–140 mm Hg systolic blood pressure), VPA was administered for 6 days (300 mg kg−1 per day). Body weights and blood pressure (BP), expression of renin-angiotensin system (RAS) components and HDAC1 were determined. The direct role of HDAC1 in the expression of RAS components was investigated using gene silencing.

Results:

HFD accelerated the increase in body weight from 22.4±1.3 to 31.9±3.0 compared to in the ND group from 22.7±0.9 to 26.0±1.7 (P=0.0134 ND vs HFD), systolic BP from 118.5±5.7 to 145.0±3.0 (P<0.001), and diastolic BP from 91.0±13.6 to 121.0±5.0 (P=0.006); BP was not altered in the ND group. HFD increased RAS components and HDAC1 in the kidneys as well as leptin in the plasma. VPA administration prevented the progression of hypertension and inhibited the increase in expression of HDAC1 and RAS components. VPA did not affect plasma leptin level. Knockdown of HDAC1 in MDCK cells decreased the expression of angiotensinogen and type 1 angiotensin II receptor.

Conclusions:

VPA prevented HFD-induced hypertension by downregulating angiotensin II and its receptor via inhibition of HDAC1, offering a novel therapeutic option for HFD-induced hypertension.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. WHOObesity and overweighthttp://www.who.int/mediacentre/factsheets/fs311/en/ 2016.

  2. Kelly T, Yang W, Chen CS, Reynolds K, He J . Global burden of obesity in 2005 and projections to 2030. Int J Obes 2008; 32: 1431–1437.

    Article  CAS  Google Scholar 

  3. Pi-Sunyer X . The medical risks of obesity. Postgrad Med 2009; 121: 21–33.

    Article  PubMed Central  Google Scholar 

  4. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME . Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015; 116: 991–1006.

    Article  CAS  PubMed Central  Google Scholar 

  5. Montani JP, Antic V, Yang Z, Dulloo A . Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes Relat Metab Disord 2002; 26 (Suppl 2): S28–S38.

    Article  CAS  Google Scholar 

  6. Robles RG, Villa E, Santirso R, Martínez J, Ruilope LM, Cuesta c et al. Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. Am J Hypertens 1993; 6: 1009–1015.

    Article  CAS  Google Scholar 

  7. Hall JE . The kidney, hypertension, and obesity. Hypertension (Dallas, Tex.: 1979) 2003; 41: 625–633.

    Article  Google Scholar 

  8. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761–1769.

    Article  CAS  Google Scholar 

  9. Dorresteijn JA, Schrover IM, Visseren FL, Scheffer PG, Oey PL et al. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens 2013; 31: 393–403.

    Article  CAS  Google Scholar 

  10. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26: 1891–1900.

    Article  CAS  Google Scholar 

  11. Thaker V, Patel K . Recent advances in pharmacotherapy of acute coronary syndrome. Int J Basic Clin Pharmacol 2017; 5: 1695–1703.

    Google Scholar 

  12. Viera AJ . Resistant hypertension. J Am Board Fam Med 2012; 25: 487–495.

    Article  Google Scholar 

  13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507–520.

    Article  CAS  Google Scholar 

  14. Arguelles AO, Meruvu S, Bowman JD, Choudhury M . Are epigenetic drugs for diabetes and obesity at our door step? Drug Discov Today 2016; 21: 499–509.

    Article  Google Scholar 

  15. Tang J, Yan H, Zhuang S . Histone deacetylases as targets for treatment of multiple diseases. Clin Sci 2013; 124: 651–662.

    Article  CAS  PubMed Central  Google Scholar 

  16. Wang Y, Miao X, Liu Y, Li F, Liu Q, Sun J et al. Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases. Oxid Med Cell Longev 2014; 2014: 641979.

    PubMed  PubMed Central  Google Scholar 

  17. Eom GH, Kook H . Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases. Pharmacol Ther 2014; 143: 168–180.

    Article  CAS  Google Scholar 

  18. FDAValproate Informationhttp://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm192645.htm 2016.

  19. NIHHIV Drugs in Developmenthttps://chemdb.niaid.nih.gov/DrugDevelopmentHIV.aspx 2016.

  20. Chateauvieux S, Morceau F, Dicato M, Diederich M . Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010; 2010: 18http://www.ncbi.nlm.nih.gov/pubmed/20798865.

    Article  Google Scholar 

  21. Shabason JE, Tofilon PJ, Camphausen K . HDAC inhibitors in cancer care. Oncology 2010; 24: 180–185.

    PubMed  Google Scholar 

  22. Cardinale JP, Sriramula S, Pariaut R, Guggilam A, Mariappan N, Elks CM et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010; 56: 437–444.

    Article  CAS  PubMed Central  Google Scholar 

  23. Li RF, Cao SS, Fang WJ, Song Y, Luo XT, Wang HY et al. Roles of HDAC2 and HDAC8 in Cardiac Remodeling in Renovascular Hypertensive Rats and the Effects of Valproic Acid Sodium. Pharmacology 2016; 99: 27–39.

    Article  Google Scholar 

  24. Rajeshwari T, Raja B, Manivannan J, Silambarasan T, Dhanalakshmi T . Valproic acid prevents the deregulation of lipid metabolism and renal renin-angiotensin system in L-NAME induced nitric oxide deficient hypertensive rats. Environ Toxicol Pharmacol 2014; 37: 936–945.

    Article  CAS  Google Scholar 

  25. Kim JI . High fat diet confers vascular hyper-contractility against angiotensin II through upregulation of MLCK and CPI-17. Korean J Physiol Pharmacol 2017; 21: 99–106.

    Article  CAS  Google Scholar 

  26. Park KM, Kim JI, Ahn Y, Bonventre AJ, Bonventre JV . Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem 2004; 279: 52282–52292.

    Article  CAS  Google Scholar 

  27. Seok YM, Lee HA, Park KM, Hwangbo M-H, Kim IK . Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 2016; 389: 799–808.

    Article  CAS  Google Scholar 

  28. Coffman TM . The inextricable role of the kidney in hypertension. J Clin Invest 2014; 124: 2341–2347.

    Article  PubMed Central  Google Scholar 

  29. Zhao L et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012; 126: 455–467.

    Article  CAS  PubMed Central  Google Scholar 

  30. Morimatsu Y et al. Development and characterization of an animal model of severe pulmonary arterial hypertension. J Vasc Res 2012; 49: 33–42.

    Article  CAS  Google Scholar 

  31. Rondelet B et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 2003; 107: 1329–1335.

    Article  CAS  Google Scholar 

  32. Wu TH, Kuo HC, Lin IC, Chien SJ, Huang LT, Tain YL et al. Melatonin prevents neonatal dexamethasone induced programmed hypertension: histone deacetylase inhibition. J Steroid Biochem Mol Biol 2014; 144: Pt B,253–259.

    Article  Google Scholar 

  33. Soltani Z, Washco V, Morse S, Reisin E . The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches. Curr Hypertens Rep 2015; 17: 7.

    Article  Google Scholar 

  34. Lan B, Hayama E, Kawaguchi N, Furutani Y, Nakanishi T . Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension. PLoS ONE 2015; 10: e0117211.

    Article  PubMed Central  Google Scholar 

  35. Brenner BM, C M, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

    Article  CAS  Google Scholar 

  36. Parish RC, Miller LJ . Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Safety 1992; 7: 14–31.

    Article  CAS  Google Scholar 

  37. Struhl K . Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998; 12: 599–606.

    Article  CAS  Google Scholar 

  38. Chen Y, Cai S, Wang J, Xu M . Valproic acid-induced histone acetylation suppresses CYP19 gene expression and inhibits the growth and survival of endometrial stromal cells. Int J Mol Med 2015; 36: 725–732.

    Article  CAS  Google Scholar 

  39. Qiao L, Schaack J, Shao J . Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 2006; 147: 865–874.

    Article  CAS  Google Scholar 

  40. Mihaylova MM, Vasquez DS, Ravnskjaer K, Denechaud PD, Yu RT, Alvarez JG et al. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 2011; 145: 607–621.

    Article  CAS  PubMed Central  Google Scholar 

  41. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 2001; 8: 1243–1254.

    Article  CAS  Google Scholar 

  42. Lee HA, Lee DY, Cho HM, Kim SY, Iwasaki Y, Kim IK et al. Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension. Circ Res 2013; 112: 1004–1012.

    Article  CAS  Google Scholar 

  43. Seok YM, Lee HA, Park KM, Hwangbo MH, Kim IK . Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 2016; 389: 799–808.

    Article  CAS  Google Scholar 

  44. Wolden-Hanson T, Gidal BE, Atkinson RL . Evaluation of a rat model of valproate-induced obesity. Pharmacotherapy 1998; 18: 1075–1081.

    CAS  PubMed  Google Scholar 

  45. Coble JP, Cassell MD, Davis DR, Grobe JL, Sigmund CD . Activation of the renin-angiotensin system, specifically in the subfornical organ is sufficient to induce fluid intake. Am J Physiol 2014; 307: R376–R386.

    CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) Grant (MSIP No. 2014R1A5A2010008 and NRF-2017R1D1A1B03032729) funded by the Korean Government.

Author information

Authors and Affiliations

  1. Department of Molecular Medicine and Medical Research Center, Keimyung University School of Medicine, Daegu, Republic of Korea

    J Choi, S Park & J I Kim

  2. Department of Immunology and Medical Research Center, Keimyung University School of Medicine, Daegu, Republic of Korea

    T K Kwon

  3. Department of Neurology and Medical Research Center, Keimyung University School of Medicine, Daegu, Republic of Korea

    S I Sohn

  4. Department of Anatomy and BK21 plus, Kyungpook National University School of Medicine, Daegu, Republic of Korea

    K M Park

Authors
  1. J Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T K Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S I Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K M Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J I Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J I Kim.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choi, J., Park, S., Kwon, T. et al. Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis. Int J Obes 41, 1702–1709 (2017). https://doi.org/10.1038/ijo.2017.166

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2017.166

This article is cited by

Search

Advanced search

Quick links